RPE65 and Leber congenital amaurosis: In 2018, the FDA approved Voretigene neparvovec (Luxturna®) as the inaugural gene therapy for LCA/EOSRD with biallelic RPE65 variants, following positive results from phase 3 clinical trial (12).